HOME >> MEDICINE >> NEWS
Cholesterol-lowering drug may slow Alzheimer's progression

NEW ORLEANS, Nov. 9 The cholesterol-lowering drug atorvastatin slowed down mental decline and improved depressive symptoms in people with Alzheimer's disease, according to a small pilot study reported at the American Heart Association's Scientific Sessions 2004.

"This is the first off-label use of a drug tested in Alzheimer's patients in the last 10 years that has shown promise of benefit," said D. Larry Sparks, Ph.D., senior scientist and head of the Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute in Sun City, Ariz.

Animal and human studies have shown that elevated cholesterol is an important risk factor for Alzheimer's disease. Based on this research and Sparks's work for the past 20 years, he and colleagues in Bethesda, Md., New York City, Phoenix and Sun City, tested the effects of lowering cholesterol in people with mild-to-moderate Alzheimer's disease.

The Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT) was a double-blind, placebo-controlled pilot study that assessed whether lowering cholesterol with atorvastatin could stabilize or improve cognition in people with mild-to-moderate Alzheimer's. Doctors administered the statin drug in addition to the cholinesterase inhibitors the patients were already taking. Cholinesterase inhibitors are the only Food and Drug Administrationapproved therapy for mild-to-moderate Alzheimer's disease. The drugs inhibit the breakdown of acetylcholine, a transmitter that is decreased in Alzheimer's patients and thought to be related to mental decline.

The researchers evaluated 46 patients -- 25 on atorvastatin 80 mg and 21 on placebo -- for one year. The participants were, on average, 78-years-old with 14 years of education. One-third of the group was female. The patients were evaluated periodically for cognition, overall mental function and depression. Alzheimer's patients are known to have depression that usually gets worse as their Alzheimer
'"/>

Contact: Darcy Spitz
darcy.spitz@heart.org
212-878-5940
American Heart Association
9-Nov-2004


Page: 1 2 3

Related medicine news :

1. Cholesterol-lowering drug may also reduce risk of blood clots
2. Cholesterol-lowering medications may reduce risk of glaucoma
3. Cholesterol-lowering drugs may help stroke patients get well
4. Cholesterol-lowering drugs safe and effective in children
5. Cholesterol-lowering drugs should revolutionise treatment of heart attack and stroke
6. Cholesterol-lowering drugs provide double protection against heart disease
7. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
8. Neuronal death and processing of Tau protein in Alzheimers disease
9. Researchers discover link between insulin and Alzheimers
10. New trials for counseling caregivers and patients with Alzheimers begin
11. Marijuana ingredient may stall decline from Alzheimers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... Responsible dental ... One must brush properly to achieve optimal results. This important necessity inspired an inventor ... need for a way to ensure that people break or avoid bad techniques of ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Lori ... Greenberg Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st ... Greenberg Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs ...
(Date:12/2/2016)... DIEGO, Calif. (PRWEB) , ... December 02, 2016 , ... ... Event at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals ... myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. ... scholarship funds for area students and operating support to UNCF-member institutions, including Miles ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Dec. 3, 2016 A highly innovative, personalized cell-based treatment for ... through clinical trials. Pediatric oncologists from Children,s Hospital of Philadelphia ... or refractory acute lymphoblastic leukemia (ALL). The physician-scientists presented findings ... San Diego . ... ...
(Date:12/2/2016)... The U.S. Food and Drug Administration today ... the risk of cardiovascular death in adult patients with ... "Cardiovascular disease is a leading cause of death ... Jean-Marc Guettier , M.D., C.M., director of the Division ... Drug Evaluation and Research. "Availability of antidiabetes therapies that ...
(Date:12/2/2016)... -- Persistence Market Research (PMR) delivers key ... titled, "Global Market Study on Cardiac Pacemaker: North America Regional ... 2016 and 2024". The global cardiac pacemaker market was valued ... likely to decline to US$ 3923.8 Mn by 2024. ... is anticipated to exhibit a declining CAGR of -0.5% ...
Breaking Medicine Technology:
Cached News: